Publications by authors named "Stephan Bart"

Claim this Profile
S
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
Christy A Comeaux, Stephan Bart, Arangassery Rosemary Bastian, Vladislav Klyashtornyy, Els De Paepe

J Infect Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.
Christine A Shaw, Allison August, Stephan Bart, Peta-Gay Jackson Booth, Conor Knightly

Vaccine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, Stephan Bart, John Ervin

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
Neil Goldstein, Viki Bockstal, Stephan Bart, Kerstin Luhn, Cynthia Robinson

J Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart

NPJ Vaccines· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of smoked cannabis on tobacco cigarette smoking intensity and subjective effects: A placebo-controlled, double-blind, within-subjects human laboratory study.
Erica N Peters, Evan S Herrmann, Carson Smith, Jess Alan Wilhelm, Bartosz Koszowski, Stephan Bart

Exp Clin Psychopharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial.
Sybil Tasker, Anna Wight O'Rourke, Anvar Suyundikov, Peta-Gay Jackson Booth, Stephan Bart

Vaccines (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Robert T Cartee, Ann Thanawastien, Thomas J Griffin Iv, John J Mekalanos, Stephan Bart

PLoS Negl Trop Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Dan H Barouch, Frank L Tomaka, Frank Wegmann, Daniel J Stieh, Galit Alter, Stephan Bart

Lancet· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.
Stephan Bart, Kevin Cannon, Darrell Herrington, Richard Mills, Eduardo Forleo-Neto

Hum Vaccin Immunother· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Judith Falloon, Fei Ji, Craig Curtis, Stephan Bart, Eric Sheldon

Vaccine· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.
Stephan A Bart, Matthew Hohenboken, Giovanni Della Cioppa, Vas Narasimhan, Philip R Dormitzer

Sci Transl Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
Stephan Bart, Joachim Marr, Konstanze Diefenbach, Dietmar Trummer, Carole Sampson-Landers

Contraception· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis